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Abstract 
Background: Selective proteinuria is frequently observed in glomerular diseases characte-
rized by podocyte injury. Although, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] has potential 
therapeutic effects on chronic kidney diseases through decr e a s i n g   p o d o c y t e   l o s s ,   t h e   m e-
chanism underlying the beneficial effects of 1,25(OH)2D3 on podocytes remains still unknown. 
The  present  study  tested  the  hypothesis  that  1,25(OH)2D3  directly  reduced  podocyte 
apoptosis and loss.  
Methods: Sprague-Dawley (SD) ra t s   w e r e   r a n d o m l y   a s s i g n e d   i n t o   t h r e e   g r o u p s :   A d r i a m y c i n  
(ADR) group (n=15), ADR+1,25-(OH)2D3 group (n=16), and control group (n=16). Rats in 
ADR+1,25-(OH)2D3 group were treated with 1,25(OH)2D3 for 8 weeks. The number of 
podocytes and foot process width (FPW) were detected by transmission electron micro-
scopy. The number of apoptotic podocytes per glomerulus and that of apoptotic nuclei and 
caspase-3 activity in cultured podocytes were determined by TUNEL staining. The average 
number of podocytes per glomerulus was quantified by immunohistochemistry. Expressions 
of p-Smad2/3, p-Smad1/5/8, Fas, Fas-Associated protein with Death Domain (FADD), Bax, 
and Bcl-2 proteins were examined by Western blot assay.  
Results: Compared with control group, proteinuria, FPW, apoptotic podocytes, caspase-3 
activity, the protein expressions
 of p-Smad2/3, Fas, FADD, and Bax were significantly in-
creased, podocyte density, p-Smad1/5/8   a n d   Bcl-2 expression were d e c r e a s e d   i n   A D R   g r o u p . 
1,25(OH)2D3  significantly  reduced  proteinuria,  FPW,  caspase-3  activity,  expressions  of 
p-Smad2/3, F a s ,   F A D D ,   a n d   B a x  a n d   a p o p t o s i s   o f   p o d o c y t e s ,   b u t   i n c r e a s e d   serum albumin, 
number of viable podocytes , p-Smad1/5/8 and Bcl-2 expression in ADR treated rats.  
Conclusion:  ADR-induced  podocyte  apoptosis  was  associated  with  the  imbalance  of 
p-Smad2/3, p-Smad1/5/8 the activity of caspase-3 and aberrant expressions of, F a s ,   F A D D ,   B a x  
and Bcl-2. The beneficial effects of 1,25(OH)2D3 on podocytes may be attributable to inhibit 
podocyte apoptosis and the amelioration of podocytopenia. 
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Introduction 
Podocytes are  highly specialized and terminally 
differentiated  cells  with  limited  mitotic  capacity. 
T h e r e f o r e ,   o n c e   l o s t ,   t h e   r e g e n e r a t i o n   o f   p o d o c y t e s   i s  
limited. There is a growing body of literature showing 
that  podocytopenia  is  a  critical  determinant  in  the 




gressive  renal  failure.  Podocytopenia  is  caused  by 
detachment  of podocytes from glomerular basement 
membrane (GBM) and/or apoptosis of podocytes (1). 
Caspase-3  is  a  newly  characterized  mammalian 
cysteine  protease  that  promotes  cell  apoptosis  in 
m a n y   d i f f e r e n t conditions. T h e   m o s t   c o m m o n   c a u s e   o f  
apoptosis in kidney diseases is mediated by Fas (2). 
Albumin overload also resulted in a dose-dependent 
up-regulation of Fas and Fas-associated protein with 
death domain (FADD) (3). Bcl-2 family which consists 
of  both  pro-apoptotic  protein  (e.g.,  Bax)  and  an-
ti-apoptotic protein (e.g., Bcl-2 )   a p p e a r s   t o   p l a y   c r u c i a l  
roles in regulating the balance between apoptosis and 
survival (4).  
It has been demonstrated that 1,25-(OH)2D3 can 
r e d u c e   p r o t e i n u r i a   i n   a c t i v e   T h y 1 -nephritis rats  (5), 
inhibit  progressive  glomerulosclerosis  and  decrease 
albuminuria  in  subtotally  nephrectomized  rats  (6), 
and  down-regulate  the  renin-angiotensin  system 
(RAS) by inhibiting renin production (7). Recent re-
ports also indicate that 1,25(OH)2D3 can decrease po-
docyte  loss  and  inhibit  podocyte  hypertrophy  in 
subtotally  nephrectomized  rats  (8).  In  puromycin 
aminonucleoside nephropathy rats, podocyte injury is 
suppressed by 1,25(OH)2D3 via modulation of trans-
forming growth factor-beta 1 (TGF-1)/bone morpho-
genetic  protein-7 (BMP-7)  signalling (9). Those  find-
i n g s   c l e a r l y   s u g g e s t   p o d o c y t e s   s e r v e   a s   a   p o t e n t i a l l y  
important  target  for  vitamin  D  in  the  treatment  of 
kidney diseases.  
Recent  studies  have  shown  that  podocytes  un-
dergo apoptosis in glomerular disease (10). Xiao et al. 
(11)  demonstrated  that  1,25(OH)2D3  prevented  pu-
romycin  aminonucleoside-induced  apoptosis  of  glo-
merular  podocytes  by  activating  the  phosphatidyli-
nositol 3-kinase/Akt-signaling pathway. Gassler et al. 
(12) revealed extensive apoptosis and markedly de-
creased number of nephrons in bcl-2 deficient mice. 
Schiffer et  al.  (13)  demonstrated  podocytes  undergo 
apoptosis at early stages in the course of progressive 
glomerulosclerosis in TGF-β1 transgenic mice. Their 
r e s u l t s   s u g g e s t e d   a   n o v e l   f u n c t i o n a l   r o l e   f o r   S m a d 7   a s  
amplifier  of  TGF-β-induced  apoptosis  in  podocytes 
and a new pathomechanism for podocyte depletion in 
progressive glomerulosclerosis. 
In clinical practice, 1,25-(OH)2D3 is widely used 
in the treatment of hypocalcemia and hyperphospha-
temia of patients with chronic kidney disease (CKD). 
However,  little  is  known  about  the  effects  of 
1,25-(OH) 2D3  on  podocyte  apoptosis  and  podocyto-
penia. The present study aimed to investigate the ef-
fects of 1,25-(OH)2D3 on podocyte apoptosis and po-
docytopenia  induced  by  adriamycin  (ADR)  and  the 
potential mechanisms.  
Materials and Methods 
Animals and experimental design 
Forty-eight  male  Sprague-Dawley  (SD)  rats 
were housed in a temperature-controlled room with   a  
1 2   h   l i g h t / 1 2   h   d a r k   c y c l e   a n d   g i v e n   ad libitum access 
to food and water. These rats were randomly divided 
i n t o   t h r e e   g r o u p s   ( n = 1 6 ,   p e r   g r o u p ) :   A d r i a m y c i n  
(ADR)  group,  ADR+1,25-(OH)2D3 group, and control 
g r o u p .   A D R   i n d u c e d   n e p h r o p a t h y   w a s   i n t r o d u c e d   b y  
a single i n j e c t i o n   o f   7 . 5   m g / k g   A D R   ( 0 . 7 5   m g / m l   i n  
n o r m a l   s a l i n e ;   S i g m a )   v i a   t h e   t a i l  vein  (14) .   R a t s   i n  
ADR+1,25-(OH) 2D3  group  were  treated  with 
1,25-(OH) 2D3 (3 ng·100 g body weight-1·day-1) (8) by a 
subcutaneous osmotic minipump for 8 weeks. One rat 
died   i n   t h e   A D R   g r o u p   a n d   w a s   e x c l u d e d   f r o m   t h e  
e x p e r i m e n t .   R a t s   i n   A D R   g r o u p   a n d   c o n t r o l   g r o u p  
w e r e   s u b c u t a n e o u s l y   g i v e n   n o r m a l   s a l i n e   o f   e q u i v a-
lent volume once daily for 8 weeks. Eight weeks later, 
24-h urine samples were collected through metabolic 
cages  followed  by  sacrifice  o f   m i c e .   T h e   2 4 -h  urine 
protein  (24  h  UP)  was  determined  by  colorimetric 
a s s a y .   L e v e l s   o f   s e r u m   a l b u m i n   ( S A ) ,   c r e a t i n i n e ,   t o t a l  
cholesterol (TC) and triglyeride (TG) were measured 
with  an  automatic  biochemical  analyzer  (HITACHI 
7080).  
Detection of podocytes and foot process width 
by transmission electron microscopy  
P a r t   o f   r e n a l   c o r t e x   w a s   f i x e d   i n   1 . 5 %   g l u t a r a l-
dehyde and 1% paraformaldehyde, dehydrated, and 
embedded  in  Spurr  resin.  Ultrathin  sections  were 
prepared and stained with lead citrate for transmis-
sion electron microscopy. Ten fields (three glomeruli 
per field) in transverse sections of each rat were ran-
domly selected under a transmission electron micro-
scope  (×3000;  Philips,  Netherlands).  The  length  of 
p e r i p h e r a l   G B M   w a s   m e a s u red  and  the  number  of 
f o o t   p r o c e s s e s   o n   G B M   w a s   c o u n t e d .   T h e   m e a n   f o o t  
process  width  (FPW)  was  calculated  as  follow: 
FPW=π/4×(∑GBM  length/  ∑foot  process);  where 
∑ G B M   l e n g t h   i s   t h e   t o t a l   l e n g t h   o f   G B M   i n   o n e   g l o-
m e r u l u s ,   ∑ f o o t   p r o c e s s   i s   t h e   t o t a l   n u m b e r   o f   foot 
process, and π/4, a correction factor, serves to correct 
the  random  orientation  under  which  foot  processes 
are sectioned (15). 
Detection of podocyte number per glomerulus 
by immunohistochemistry  
Renal tissues were fixed in formalin, embedded 
in paraffin and cut into sections followed by staining 
with periodic-acid  schiff (PAS) reagent. The number 
of podocytes in 3-µm frozen sections was determined 




mor  antigen-1  (WT-1)  polyclonal  antibody  (1:50) 
(Santa  Cruz  Biotechnology,  Inc.,  USA)  and  mouse 
anti-synaptopodin  monoclonal  antibody  (1:50)  (Bio-
friendship Inc., Beijing, China). Cells positive for both 
synaptopodin and WT-1   w e r e   c o u n t e d   i n   3 0   g l o m e r u l i  
of transverse sections. Results were presented as av-
e r a g e   n u m b e r   o f   p o d o c y t e s   p e r   g l o m e r u l u s   i n   t r a n s-
verse sections. 
Detection of apoptotic podocytes per glomeru-
lus by TUNEL staining  
Apoptotic nuclei were detected through a trans-
ferase-mediated  dUTP  nick-end  labeling  (TUNEL) 
staining of kidney sections followed by counterstain-
ing  with  hematoxylin  and  PAS,  as  previously  de-
scribed (13) .   T U N E L   s t a i n i n g   w a s   p e r f o r m e d   a c c o r d-
ing  to  the  manufacturer’s  instructions  (Biosynthesis 
Biotechnology Co., Ltd, Beijing). In brief, 3 µm paraf-
fin-embedded  kidney  sections  were  deparaffinized 
w i t h   x y l e n e ,   b l o c k e d   w i t h   3 %   H 2O2  for  30  min, 
w a s h e d   w i t h   P B S ,   p e r m e a b i l i z e d   w i t h   0 . 5 %   T r i t o n  
X-100 for 10 min and then washed with PBS. Terminal 
deoxynucleotidyl  transferase  (TdT)  and  bio-
tin-11-dUTP were supplemented followed by incuba-
tion for 60 min. Then, sections were washed with PBS, 
incubated  with  avidin-biotinylated  horseradish  pe-
roxidase  complex  followed  by  color  development 
with DAB. Counterstaining for nuclei, dehydration, 
clearing and  mounting  were  performed.  Cells  with 
brown granules in nuclei were TUNEL positive cells 
a n d   T U N E L   p o s i t i v e   p o d o c y t e s   o n   t h e   G B M   w e r e  
counted in 30 glomeruli of transverse section, Results 
were  expressed  as  average  numbers  of 
TUNEL-positive podocytes per glomerulus.  
Detection of apoptotic podocytes nuclei and the 
activity of caspase-3 in cultured podocytes  
Podocytes  were  isolated  from  glomeruli  of  SD 
rats  and  maintained  in  medium  as  previously  de-
scribed (16). Briefly, glomeruli were isolated by dif-
ferential sieving of minced cortices, followed by di-
gestion with collagenase and culture. Early cellular 
outgrowths at 5-7 days were selectively removed by a 
cylinder cloning technique. Cells were replated, and 
plates growing pure colonies were then expanded and 
identified. Podocytes between passages 8 and 10 were 
used  for  experiments.  Terminal  deoxynucleotidedyl 
transferase  (TUNEL)  assay  (ApoAlert Assay  Kit;  BD 
Biosciences Clontech, San Jose, CA) was performed as 
previously described (17). Briefly, cells were grown on 
cover slips, fixed with 4% formaldehyde for 30 min at 
4 ° C ,   p e r m e a b i l i z e d   w i t h   0 . 2 %   T r i t o n   X -100 f o r   1 5   m i n  
a t   4 ° C ,   a n d   i n c u b a t e d   w i t h   a   m i x t u r e   o f   n u c l e o t i d e s  
and TdT enzyme for 60 min at 37°C in humidified air 
in  dark.  Reaction  was  terminated  with  2X SSC, and 
the cover slips were mounted on glass slides. Apop-
totic nuclei were detected under fluorescence micro-
scope,  and  cells  with  characteristic  morphology  of 
apoptosis,  including  nuclear  fragmentation,  nuclear 
condensation,  and  intensely  fluorescent  nuclei were 
c o u n t e d .   A   t o t a l   o f   1 0 0   c e l l s   w e r e   c o u n t e d   f o r   e a c h  
sample. Results were expressed as the percentage of 
TUNEL  positive  nuclei  in  all  nuclei  visualized  by 
phase contrast microscope.  
Detection  of  caspase-3  activity  was  performed 
with  B D   A p o A l e r t   C a s p a s e   C o l o r i m e t r i c   A s s a y   K i t  
( B D   B i o s c i e n c e s ,   P a l o   A l t o ,   C A ) ,   a c c o r d i n g   t o   t h e  
manufacturer’s instructions. This assay uses the spec-
trophotometric  detection  of  the  chromophore 
p-nitroaniline after its cleavage by caspase-3   f r o m   t h e  
labeled  caspase-specific  substrates.  Adherent  cells 
t o g e t h e r   w i t h   f l o a t i n g   c e l l s   i n   t h e   m e d i u m   w e r e   c o l-
lected, and lysed with lysis buffer included in the kit. 
A f t e r   t h e   c e l l   l y s a t e   w a s   i n c u b a t e d   w i t h   c a s p a s e -3 
substrate  DEVD–p-nitroaniline  (final  concentration, 
50 µ M )   a t   3 7 ° C   f o r   1   h ,   t h e   a b s o r b a n c e   (caspase-3 ac-
tivity) was measured by at 405 nm with a  microplate 
reader (Packard Spectracount). 
Western blot assay  
After removal of kidney capsule, the outer cortex 
w a s   m i n c e d   i n   1 - to 2-mm fragments, passed through 
consecutive 80- and  120-mesh sieves, and recovered 
from the 200-mesh sieve. After centrifugation, super-
natant was abandoned and glomeruli were obtained. 
Glomeruli were ly s e d   w i t h   R I P A   b u f f e r   ( 0 . 1 %  sodium 
dodecyl sulfate, 1% sodium deoxycholate, 1% Triton 
X-100,  150  mM  NaCl,  10  mM  EDTA,  and  25  mM 
Tris·HCl,  pH  7.2)  and  protease  inhibitors  (1  mM 
phenylmethylsulfonyl  fluoride,  1  µg/ml  leupeptin, 
and  1  µg/ml  pepstatin) followed  by  ultrasonic  ho-
mogenation on ice. Lysates were centrifuged at 12,000 
g  for 10 min, and  supernatants  containing  proteins 
were  collected.  Then,  75  μg  of  total  proteins  were 
subjected  to  SDS-polyacrylamide gel electrophoresis 
and transferred onto nitrocellulose membranes. After 
being  blocked  in  5%  low-fat  milk,  the  membranes 
were  incubated  with  anti-p-smad2/3(1:500),  an-
ti-p-Smad1/5/8(1:500), anti-Fas  (1:1000), anti-FADD 
(1:100), anti-Bax (1:500) or anti-Bcl2 (1:500) antibodies 
(Santa  Cruz  Biotechnology,  CA).  Subsequently,  the 
membranes were rinsed in Tris-buffered saline con-
taining 0.02% Tween-20 and incubated with horsera-
d i s h   p e r o x i d a s e   c o n j u g a t e d   t o   a n t i -rabbit or  mouse 
I g G   a n t i b o d y   ( 1 : 4 0 0 0 ,   S a n t a   C r u z ) .   A f t e r   w a s h i n g ,   t h e  
membranes were developed using an enhanced che-
miluminescence reagent (Santa Cruz), and the specific 




s i o n   o f   s p e c i f i c   p r o t e i n   w a s   n o r m a l i z e d   b y   t h a t   o f  
GAPDH (36 kDa) as an endogenous reference. 
Statistical Analyses  
Data were presented as means ± standard devi-
ation  (SD).  Results  were  analyzed  using  the 
Kruskal-Wallis  non-parametric  test  for  multiple 
comparisons  followed  by  Mann-Whitney  U-test.  A 
value of P<0.05 was considered statistically signifi-
cant. Correlations were assessed by Pearson correla-
tion analysis. Statistical analyses were performed with 
SPSS version 11.0.  
Results 
Changes in 24 h UP, SA, TC and TG  
The levels of 2 4   h   U P ,   T C   a n d   T G   i n   A D R   g r o u p  
were significantly higher than those in control group, 
and the SA level i n   A D R   g r o u p   w a s  markedly lower 
than  that  in c o n t r o l   g r o u p .   A s   c o m p a r e d   w i t h   A D R  
group, the levels o f   2 4   U P ,   T C   a n d   T G   w e r e   dramati-
cally decreased and SA increased after 1,25-(OH)2D3 
treatment. Results are shown in Table 1.  
Table 1 24 h UP, SA, TC and TG levels in different groups 
Group  n  24 h UP 
(mg) 
SA (g/L)  TC 
(mmol/L) 
TG (mmol/L) 
control  16 1.01±0.29  35.10±3.33  0.43±0.11  0.89±0.21 








Data are means ± SD. 24 h UP, 24-h urine protein; SA, serum albu-
min; TC, total cholesterol; TG, triglyeride.  
##P < 0.01, #P < 0.01 vs. control group.  
△△P<0.01 vs. ADR group. 
 
The number of podocytes and FPW 
C o m p a r e d   w i t h   r a t s   i n   c o n t r o l   g r o u p ,   t h e   n u m-
ber of podocytes was decreased and FPW increased in 
ADR group. In addition, after 1,25-(OH)2D3 treatment, 
the  number  of  podocytes  and FPW  in  1,25-(OH)2D3 
g r o u p   w a s   h i g h e r   a n d   s m a l l e r   t h a n   t h o s e   i n   ADR 
group, respectively (Table 2 and Figure 1).  
Table 2 The number of podocytes and FPW in different 
groups  
Group  n  Podocytes  FPW (nm) 
control  16  5.46±0.51  271.38±52.48 
ADR  15  3.35±0.14##  806.13±120.19## 
ADR +1,25(OH)2D3  16  4.44±0.23## △△  401.13±52.48## △△ 
Data are means ± SD. FPW, foot process width.  
##P < 0.01 vs. control group.  
△△P<0.01 vs. ADR group. 
 
Effect of 1,25(OH)2D3 treatment on podocyte 
density 
I n   t h e   c o n t r o l   g r o u p ,   t h e   n u m b e r   o f  
double-positive  podocytes  was  11.55±1.69 
cells/glomerulus. In the ADR group, the number of 
double-positive  podocytes  (7.97±1.62 
cells/glomerulus) was markedly lower  than  that  in 
1,25(OH)2D3  group  (10.07±1.54  cells/glomerulus)  (P 
<0.01) (Figure 2).  
Podocyte apoptosis  
TUNEL  staining  was  performed  to  detect  the 
number of apoptotic podocytes per glomerulus. Sig-
nificant difference in the number of TUNEL-positive 
podocytes was found between ADR group and con-
trol group (2.50±0.77 vs. 0.19±0.40, P<0.01).  After  8 
weeks of treatment with 1,25(OH)2D3,   t h e   n u m b e r   o f  
apoptotic podocytes was significantly higher than that 
in ADR group (1.19±0.37 vs. 2.50±0.77, P<0.01), indi-
cating  marked  improvement  in  podocyte  apoptosis 
after 1,25(OH)2D3 treatment (Figure 3). 
 
 
F i g u r e   1 . Ultrastructure of podocytes under a transmission electron microscope (×3000). A :   c o n t r o l   g r o u p ;   B :   A D R   g r o u p  
a n d   C :   1,25(OH) 2D3 group. The foot processes in the control group were intact. Fusion and disappearance of foot processes 
(arrow) were noted in the ADR group. Fusion and disappearance of foot processes were improved in 1,25(OH)2D3 group 





Figure 2. Podocytes in different groups under a light microscope (×200). Immunohistochemistry was performed to eva-
luate the number of podocytes. A: control group; B: ADR group and C: 1,25(OH)2D3 group. The average number of 
double-positive podocytes (arrow)
 was 11.55±1.69 cells/glomerulus in the control group, and 7.97±1.62 cells/glomerulus in 
the A D R   g r o u p . Statistical analysis showed the average number of podocytes per glomerulus
 was higher in the 1,25(OH)2D3 




Figure  3. Apoptotic podocytes in different groups (×400). T U N E L   s t a i n i n g   w a s   p e r f o r m e d   t o   d e t e c t   t h e   n u m b e r   o f  
apoptotic podocytes per glomerulus. A: control group; B: ADR group and C: 1,25(OH)2D3 group. The average number of 
TUNEL-positive podocytes (arrows) was 0.19±0.40 cells/glomerulus i n   t h e   c o n t r o l   g r o u p   a n d   2.50±0.77 cells/glomerulus in 
t h e   A D R   g r o u p . Statistical analysis showed the number of TUNEL-positive podocytes
 was lower in 1,25(OH)2D3-treated 
group (1.19±0.37 cells/glomerulus) than in the ADR group. 





TUNEL s t a i n i n g   w a s   c o n d u c t e d   i n   c u l t u r e d   p o-
docytes  treated  with  1,25(OH)2D3.  Representative 
photographs  of  apoptotic  podocytes  from  fluores-
cence  microscopy  were  shown  in  Figure  4.  In  the 
control  group,  TUNEL  positive  podocytes  were  al-
most absent, and the morphology of necrotic cells was 
also not observed. The arrows revealed nuclear con-
densation and fragmentation, characteristics of apop-
tosis  in  ADR  group.  Less  apoptotic  podocytes  in 
1,25(OH)2D3 g r o u p   w a s   f o u n d   w h e n   c o m p a r e d   w i t h  
ADR  group.  These  results  further  confirmed  that 
1,25(OH)2D3 could improve podocyte apoptosis.  
Detection of caspase-3 activity 
The caspase-3 activity was 0.13±0.05 OD405/mg 
p r o t e i n   i n   c o n trol group, 0.42±0.11 OD405/m g   p r o t e i n  
in  ADR g r o u p   a n d   0 .33±0.09 OD405/mg  protein in 
1,25(OH)2D3  group.  The  caspase-3  activity  in  ADR 
group was 3.23 fold higher than that in control group 
(P < 0.01), and after 8 weeks of 1,25(OH)2D3 treatment, 
caspase-3 activity was down-regulated by 21.4% (P < 
0.05 versus ADR group). 
Western Blot  
T h e   s p e c i f i c   p r o t e i n   b a n d s   o f   p-Smad2/3, 
p-Smad1/5/8, F a s ,   F A D D ,   B a x ,   B c l -2,  and  GAPDH 
were identified as 55 kDa, 60 kDa, 50 kDa, 25 kDa, 23 
k D a ,   2 6   k D a   a n d   3 6   k D a ,   r e s p e c t i v e l y .  The expressions 
of  p-Smad2/3, p-Smad1/5/8, Fas,  FADD,  Bax,  and 
Bcl-2  were  0.68±0.10,  1.10±0.20,  0.12±0.08,  0.12±0.06, 
0.24±0.09, and 0.86 ± 0.15, respectively, in the control 
group,  1.04±0.22,  0.79±0.12,  0.52±0.13,  0.44±0.11, 
0.61±0.12, and 0.23 ± 0.07, respectively, in the ADR 
group,  and 0.83±0.21, 0.95±0.17,  0.31±0.09, 0.35±0.10, 
0.34±0.10,  and  0.61±0.13,  respectively,  in  the 
1,25(OH)2D3-treated  group.  The  expressions  of 
p-Smad2/3, F a s ,   F A D D ,   a n d   B a x   w e re significantly 
higher and p-Smad1/5/8, Bcl-2 expression lower in 
t h e   A D R   g r o u p   than those in the control group. The 
decrease in the expressions of p-Smad2/3, Fas, FADD, 
Bax,  and  Bcl-2  and  increase  in  p-Smad1/5/8,  Bcl-2 
expression  were  observed  in  1,25-(OH)2D3  group 
when compared with the ADR group (Figure 5).  
 
Figure 4. Tunel-positive nuclei in cultured podocytes (arrows) (×400). Podocytes from passages 8 to 10 were used for 
Tunel staining and all nuclei
 visualized under a phase contrast microscope. The apoptotic nuclei (arrows identify) underwent 
nuclear fragmentation and condensation, characteristics of apoptosis. A: control group;   B :   A D R   g r o u p  a n d   C :   1,25(OH)2D3 
group. The percentage of TUNEL-positive nuclei was 2±0.5% in the control group and 14.5±2.3% in the ADR group. The 
1,25(OH)2D3 treated group had lower number (5.4±1.1%) o f   T U N E L -positive nuclei in cultured podocytes than A D R   g r o u p  
did. 
##P < 0.01 vs. control group;
 △△P < 0.01,





Figure 5. Western blot assay of expressions of p-Smad2/3, p-Smad1/5/8, F a s ,   F A D D ,   B a x ,   a n d   B c l -2 in different groups. 
Compared with the control group, the ADR group had higher expressions
 of p-Smad2/3, Fas, FADD, and Bax and lower 
p-Smad1/5/8, Bcl-2 expression. In addition, compared with ADR group, the expressions of p-Smad1/5/8, Fas, FADD, Bax, 
a n d   B c l -2   w e r e   d o w n -regulated and p-Smad2/3, Bcl-2   e x p r e s s i o n   w a s   u p -regulated after 1,25(OH)2D3 treatment. Data were 
expressed as means ± SD. 
##P < 0.01,
 #P < 0.05 vs. control group; △△P < 0.01,
 △P < 0.05 vs. ADR group. 
 
Discussion 
Podocytopenia  is  closely  associated  with  the 
development  of  glomerulosclerosis  in  animal  and 
human glomerular diseases. Kriz e t   a l .   ( 18) proposed 
that  podocytopenia  as  a  result  of  apoptosis  and/or 
detachment o f   p o d o c y t e s   f r o m   G B M   a n d   t h e   i n a b i l i t y  
of podocytes to replicate could result in glomerulos-
clerosis. Podocyte apoptosis is a major factor inducing 
podocytopenia (19) .   I n   m u r i n e   t y p e   1   a n d   t y p e   2   d i-
abetic models, podocyte apoptosis precedes podocyte 
depletion  and  urinary  albumin  excretion  (UAE), 
suggesting  that  podocyte  apoptosis/depletion 
represents a novel early pathomechanism leading to 
diabetic nephropathy (20).  
1,25-(OH) 2D3  can act as an immunomodulator 
a n d   m a y   b e   b e n e f i c i a l   f o r   a   n u m b e r   o f   a u t o i m m u n e  




on glomerular structures may lead to proteinuria re-
duction in several animal models (22, 23) and human 
kidney diseases (24, 25). Moreover, 1,25-(OH) 2D3 can 
decrease  podocytopenia  and  podocyte  hypertrophy 
also contributing to improved albuminuria and glo-
m e r u l o s c l e r o s i s   ( 8 ) .   I n   o u r   s t u d y ,   t h e   n u m b e r   o f  
apoptotic podocytes was determined by TUNEL assay 
in vivo and  in  vitro,  and  consistent  results  were  ob-
tained  that  1,25-(OH)2D3  significantly protected po-
docytes  from  ADR  induced  apoptosis.  Of  interest, 
1,25-(OH) 2D3  and  its  metabolites  were  previously 
found  to  induce  apoptosis  of  embryonic  renal  cells 
(26),  breast cancer cells (27, 28),  ovarian  cancer  cells 
(29), and prostate cancer cells (30) .   I n   c o n t r a s t , some 
studies  also  showed  1,25-(OH) 2D3  could  inhibit 
apoptosis  of other  cell  types  including  human leu-
kemic cells (31) and murine fibroblast cells (32).  
T o   e x p l o r e   t h e   p o t e n t i a l   m e c h a n i s m s   o f  
ADR-induced  podocyte  apoptosis  and  the  mechan-
isms  underlying  the  anti-apoptotic  effect  of 
1,25(OH)2D3,  the  expressions  of  apoptosis  related 
proteins  including  F a s ,   F A D D ,   B a x   a n d   B c l -2  and 
caspase-3  activity  were  detected.  Proteinuria  can 
cause tubular cell apoptosis which is associated with 
activation of Fas-FADD-caspase 8 pathway (33). Bcl-2 
can  bind  Bax  to  exert  its  effects.  Therefore, 
over-expression of Bcl-2 can inactivate Bax suppress-
ing  apoptosis  (34) ,   Q i u   e t   a l . ( 3 5)  showed  that 
over-expression of Bcl-2   i n   p o d o c y t e s   m a y   e x e r t   p r o-
tective  effects  on  glomerular  lesions  in  progressive 
IgA  nephropathy  through  affecting  the  Bax/Bcl-2 
ratio and finally limiting glomerular cell apoptosis. 
Our  study  demonstrates  the  protective  effect  of 
1,25-(OH) 2D3  on  podocyte  apoptosis  by 
down-regulating  Fas,  FADD  and  Bax  and 
up-regulating Bcl-2 ,   w h i c h   i s   o f   g r e a t   i m p o r t a n c e   i n  
preventing podocytopenia.  
TGF-β1  and  BMP-7  belong  to  transforming 
growth factor superfamily. In the podocytes, proteins 
o f   S m a d s   f a m i l y   p l a y   a n   i m p o r t a n t   r o l e   i n   t h e   s i g n a l  
transduction from cell membrane to nucleus. TGF-β1 
can activate smad2/3 mediating podocyte apoptosis. 
BMP-7  can  activate  PI3K/Akt /S m a d  l / 5 / 8   p r e -
t e c t i n g  p o d o c y t e s  ( 3 6 ) .  I n  t h e  p r e s e n t  s t u d y ,  
1,25(OH)2D3 t r e a t m e n t   d e c r e a s e d   t h e   p-s m a d   2 / 3  
e x p r e s s i o n   a n d   i n c r e a s e d   p-S m a d   l / 5 / 8   e x p r e s -
si o n   i n   t h e   A D R   t r e a t e d   r a t s ,   w h i c h   s u g g e s t e d  
1,25(OH)2D3 c o u l d   s u p p r e s s   TGF-β1 signal pathway 
and caspase-3 activity, inhibit expressions of apopto-
sis  related  proteins  (Fas,  FADD  and  Bax),  increase 
anti-apoptotic protein expression and activate BMP-7 
s i g n a l   p a t h w a y .   T h e s e   p r o c e s s e s   f i n a l l y   a l l e v i a t e   p o-
docyte apoptosis a n d   p r o m o t e   p o d o c y t e   s u r v i v a l .  
O u r   r e s u l t s   w e r e   c o n s i s t e n t   w i t h   X i a o   e t   a l   r e -
p o r t e d   (9,  11)  in  which  the  p r o t e c t i v e   e f f e c t s   o f  
1 , 2 5 ( O H ) 2D3  o n  p o d o c y t e s  w e r e  m e d i a t e d  b y  
T G F -β 1 / B M P -7  a n d   r e l a t e d   t o   t h e   a c t i v a t i o n   o f  
P I 3 K / A k t   l e a d i n g   t o   s u p p r e s s i o n   o f   p o d o c y t e  
a p o p t o s i s .  
Angiotensin II, TGF-β1 (37), and reactive oxygen 
species (ROS) (38)   h a v e   b e e n   s h o w n   t o   i n i t i a t e   p o d o-
c y t e   a p o p t o s i s .   F o r n o n i   e t   a l .   ( 39) reported that hepa-
tocyte  growth  factor  (HGF)  could protect podocytes 
from cyclosporine A-induced apoptosis. 1,25(OH)2D3 
exerts the protective effect on kidney in multiple ways 
such as anti-inflammation, suppression of renin pro-
duction,  and  reduction  of  fibrogenic  cytokine  pro-
duction by regulating Smad3 and  TGF-β pathways 
a n d   i n d u c i n g   H G F   m R N A   e x p r e s s i o n   a n d   H G F   s e-
cretion in renal interstitial fibroblasts (40) .   S o   i t   w a s  
possible that 1,25-(OH)2D3 could exert anti-apoptotic 
effect and prevent podocytopenia. Our results were 
partially  consistent  with  a  recent  study  in  which 
dexamethasone could prevent puromycin aminonuc-
leoside  induced  podocyte  apoptosis  (41).  Podocyto-
penia is usually found in type 2 diabetic nephropathy 
and related to increased proteinuria (42). 
 In  summary,  we  demonstrated  that 
1,25-(OH) 2D3  could  inhibit  podocyte  apoptosis 
through  changing  the  imbalance  of 
p-Smad2/3/p-Smad1/5/8,  down-regulating  cas-
pase-3   a c t i v i t y ,   a n d   expressions of F a s ,   F A D D   a n d   B a x  
and  up-regulating  Bcl-2  expression,  which  maybe 
finally contributed to improved podocytopenia. These 
findings  provides  an  experimental  evidence  for 
1,25(OH)2D3 treatment  of  nephropathy  characterized 
by podocyte injury.  
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